Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing

被引：138

作者：

Placencio, Veronica R. ^{[1
,2
]}

DeClerck, Yves A. ^{[1
,2
,3
]}

机构：

[1] Univ So Calif, Dept Pediat, Div Hematol Oncol & Blood & Bone Marrow Transplan, Los Angeles, CA 90089 USA

[2] Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA

[3] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA USA

来源：

CANCER RESEARCH | 2015年 / 75卷 / 15期

基金：

美国国家卫生研究院;

关键词：

FIBROSARCOMA CELLS; PAI-1; INHIBITOR; BREAST-CANCER; TUMOR-GROWTH; WILD-TYPE; UROKINASE; TYPE-1; ANGIOGENESIS; DEFICIENT; BINDING;

D O I：

10.1158/0008-5472.CAN-15-0876

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents. (C) 2015 AACR.

引用

页码：2969 / 2974

页数：6

共 50 条

[1] Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination
Nakatsuka, Erika
Sawada, Kenjiro
Nakamura, Koji
Yoshimura, Akihito
Kinose, Yasuto
Kodama, Michiko
Hashimoto, Kae
Mabuchi, Seiji
Makino, Hiroshi
Morii, Eiichi
Yamaguchi, Yoichi
Yanase, Takeshi
Itai, Akiko
Morishige, Ken-ichirou
Kimura, Tadashi
ONCOTARGET, 2017, 8 (52): : 89887 - 89902
[2] Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by a Small-Molecule Antagonist
Lin, Zhonghui
Jensen, Jan K.
Hong, Zebin
Shi, Xiaoli
Hu, Lihong
Andreasen, Peter A.
Huang, Mingdong
CHEMISTRY & BIOLOGY, 2013, 20 (02): : 253 - 261
[3] Plasminogen activator inhibitor-1 in cancer research
Li, Sijing
Wei, Xiaohui
He, Jinyong
Tian, Xuemei
Yuan, Shengtao
Sun, Li
BIOMEDICINE & PHARMACOTHERAPY, 2018, 105 : 83 - 94
[4] Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer
Mashiko, Satsuki
Kitatani, Kazuyuki
Toyoshima, Masafumi
Ichimura, Atsuhiko
Dan, Takashi
Usui, Toshinori
Ishibashi, Masumi
Shigeta, Shogo
Nagase, Satoru
Miyata, Toshio
Yaegashi, Nobuo
CANCER BIOLOGY & THERAPY, 2015, 16 (02) : 253 - 260
[5] The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding
Kubala, Marta Helena
DeClerck, Yves Albert
CANCER AND METASTASIS REVIEWS, 2019, 38 (03) : 483 - 492
[6] Does Plasminogen Activator Inhibitor-1 Drive Lymphangiogenesis?
Bruyere, Francoise
Melen-Lamalle, Laurence
Blacher, Silvia
Detry, Benoit
Masset, Anne
Lecomte, Julie
Lambert, Vincent
Maillard, Catherine
Hoyer-Hansen, Gunilla
Lund, Leif R.
Foidart, Jean-Michel
Noel, Agnes
PLOS ONE, 2010, 5 (03):
[7] Plasminogen Activator Inhibitor-1 A Novel Therapeutic Target for Hypertension?
Simon, Daniel I.
Simon, Norman M.
CIRCULATION, 2013, 128 (21) : 2286 - 2288
[8] Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer
Hofmann, R
Lehmer, A
Hartung, R
Robrecht, C
Buresch, M
Grothe, F
JOURNAL OF UROLOGY, 1996, 155 (03): : 858 - 862
[9] Protumorigenic Activity of Plasminogen Activator Inhibitor-1 Through an Antiapoptotic Function
Fang, Hua
Placencio, Veronica R.
DeClerck, Yves A.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (19): : 1470 - 1484
[10] Therapeutic Value of Small Molecule Inhibitor to Plasminogen Activator Inhibitor-1 for Lung Fibrosis
Huang, Wen-Tan
Vayalil, Praveen K.
Miyata, Toshio
Hagood, James
Liu, Rui-Ming
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2012, 46 (01) : 87 - 95

← 1 2 3 4 5 →